GLYNAMIC-MV 3/0.3MG TAB

Distributor inventory | Tablet

Type 2 diabetes mellitus to improve blood glucose control when diet and exercise alone are not adequate; may be used when dual therapy is required for post‑meal and fasting glucose control.

Glimepiride (a sulfonylurea) increases insulin release from the pancreas and improves insulin sensitivity. Voglibose (an alpha‑glucosidase inhibitor) delays intestinal carbohydrate digestion and absorption, reducing post‑meal blood sugar spikes.

Take orally as prescribed by the doctor, usually once daily with the first main meal (or just before meals as advised). Swallow whole with water; do not skip meals after taking it. Monitor blood glucose regularly.

Hypoglycaemia, dizziness, headache, nausea, abdominal pain, flatulence, diarrhoea, bloating, increased liver enzymes

Risk of low blood sugar—more likely with missed meals, alcohol, strenuous exercise, or with other antidiabetics; carry glucose. Use with caution in kidney or liver impairment and in elderly patients. Not recommended in type 1 diabetes or diabetic ketoacidosis. Seek medical help for severe abdominal pain, jaundice, or allergic reactions. Regular monitoring of blood glucose, HbA1c, and liver function may be advised.

Other antidiabetics/insulin (increased hypoglycaemia), alcohol (may increase hypoglycaemia), beta-blockers (may mask hypoglycaemia symptoms), corticosteroids and thiazide diuretics (may raise glucose), ACE inhibitors (may enhance glucose-lowering), fluoroquinolones (glucose disturbances), NSAIDs/salicylates (may increase sulfonylurea effect), azole antifungals and macrolides (may increase glimepiride levels)

Store below 25°C in a cool, dry place away from moisture and direct light. Keep in original blister pack and out of reach of children.

Glimepiride 3 mg + Voglibose 0.3 mg tablets (various brands), Zoryl MV 3.0 Tablet, Amaryl MV 3 Tablet, Glimy MV 3 Tablet, Glynase-MV 3 Tablet